Tweet
Joint (NASDAQ:JYNT) was upgraded by Zacks Investment Research from a "hold" rating to a "buy" rating in a note issued to investors on Wednesday. The firm presently has a $9.75 price objective on the stock. Zacks Investment Research 's target price would indicate a potential upside of 14.57% from the company's current price.
According to Zacks, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " Get Joint alerts:
A number of other equities analysts also recently issued reports on the stock. Roth Capital reiterated a "buy" rating on shares of Joint in a research note on Friday, August 10th. ValuEngine downgraded shares of Joint from a "strong-buy" rating to a "buy" rating in a research note on Monday, July 2nd. Finally, Maxim Group reiterated a "buy" rating and set a $10.00 price objective on shares of Joint in a research note on Friday, May 11th. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of "Buy" and an average price target of $10.58. Shares of JYNT stock opened at $8.51 on Wednesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.17 and a current ratio of 1.17. The stock has a market capitalization of $125.06 million, a price-to-earnings ratio of -34.04 and a beta of 0.90. Joint has a one year low of $3.71 and a one year high of $9.64.
Joint (NASDAQ:JYNT) last issued its earnings results on Thursday, August 9th. The company reported $0.01 EPS for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.02. Joint had a negative net margin of 3.72% and a negative return on equity of 29.55%. The business had revenue of $7.56 million for the quarter, compared to the consensus estimate of $7.62 million. equities analysts forecast that Joint will post 0.06 EPS for the current fiscal year.
In other news, CFO John P. Meloun sold 40,539 shares of the stock in a transaction that occurred on Thursday, June 28th. The shares were sold at an average price of $8.01, for a total transaction of $324,717.39. Following the transaction, the chief financial officer now directly owns 18,922 shares in the company, valued at $151,565.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website . 3.20% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bard Associates Inc. boosted its stake in shares of Joint by 12.7% during the first quarter. Bard Associates Inc. now owns 75,450 shares of the company's stock valued at $517,000 after purchasing an additional 8,500 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Joint by 276.5% during the second quarter. Acadian Asset Management LLC now owns 142,127 shares of the company's stock valued at $1,162,000 after purchasing an additional 104,373 shares in the last quarter. Boston Partners boosted its stake in shares of Joint by 48.0% during the first quarter. Boston Partners now owns 285,431 shares of the company's stock valued at $1,955,000 after purchasing an additional 92,631 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Joint during the fourth quarter valued at approximately $379,000. Finally, Deutsche Bank AG boosted its stake in shares of Joint by 3,839.1% during the fourth quarter. Deutsche Bank AG now owns 59,087 shares of the company's stock valued at $293,000 after purchasing an additional 57,587 shares in the last quarter. Hedge funds and other institutional investors own 46.38% of the company's stock.
Joint Company Profile
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of December 31, 2017, the company operated 352 franchised clinics and 47 company-owned or managed clinics.
Get a free copy of the Zacks research report on Joint (JYNT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter 